Metabolomic Analysis of Systemic Sclerosis

Status: Terminated
Location: See all (4) locations...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years. The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of vascular lesions, by comparing the profiles of SSc beginners (\<3 years) to established forms (\> 3 years). Secondary purposes: * Prognosis: to study the metabolomics profile of SSc when a visceral complication occurs * Diagnosis: to compare the metabolomics profile of SSc to undifferentiated connective tissue disease (UCDT), Raynaud's disease (RD), vascular disease (VD) and healthy controls * Exploratory: to compare the metabolomics profile of blood, urine and skin of SSc patients

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)

• Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998)

• Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease

• Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke

• Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)

Locations
Other Locations
France
CHU
Dijon
Hôpitaux privés de Metz
Metz
CHU
Reims
Hôpitaux Universitaires de Strasbourg
Strasbourg
Time Frame
Start Date: 2014-12
Completion Date: 2025-04-24
Participants
Target number of participants: 121
Treatments
Scleroderma (SSc) patients (beginners and established forms).
Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)~Biological samples (skin, urine and blood):~* 1st point at patient's inclusion visit~* 2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)
Undifferentiated Connective Tissue Disease (UCDT) patients
Patients with criteria proposed by Mosca et al. (1998)~Biological samples (skin, urine and blood):~\- 1single point at patient's inclusion visit
Raynaud disease patients
Patients with primary and isolated Raynaud disease~Biological samples (skin, urine and blood):~\- 1single point at patient's inclusion visit
Vascular disease patients
Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)~Biological samples (skin, urine and blood):~\- 1single point at patient's inclusion visit
Healthy control subjects
Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)~Biological samples (skin, urine and blood):~\- 1single point at patient's inclusion visit
Authors
François François
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.